上海药明生物技术有限公司 WuXi Biologics Mediaroom

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract ...

2026-06-08 16:09 2039

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-06-05 10:45 6804

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year

SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2026-06-03 10:35 3627

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2026-05-27 17:14 5259

WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization

TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, D...

2026-05-20 13:44 4295

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2026-05-13 11:33 3731

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

* Contributing to the United Nations Sustainable Development Goals, driving equitable access to h...

2026-04-29 20:30 4594

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract ...

2026-04-24 19:03 3496

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...

2026-04-23 14:14 3649

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

* Company is among the first in China's drug-device combination products sector to obtain this ce...

2026-04-15 10:39 3528

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-30 13:33 6418

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-25 18:22 5943

WuXi Biologics Reports Record 2025 Annual Results

* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew ov...

2026-03-24 19:44 5034

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffir...

2026-03-22 09:30 4276

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2026-03-13 11:09 4767

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-03-02 11:21 6402

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Researc...

2026-02-03 11:22 9477

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-29 10:39 9258

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Researc...

2026-01-26 17:35 16076

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...

2026-01-15 12:00 7995

Latest News